SLC2A1 and neoplasm: The enhanced tumor-targeting ability stems from exposed Rk1 glycosides that reduce plasma protein adhesion, prolonging circulation time, while simultaneously binding to GLUT1 protein highly expressed in tumor cells, thereby promoting accumulation in tumor tissues.